Three robust European stocks to ride the recovery
Professional investor Nick Edwards of the Guinness European Equity Income Fund picks three European stocks that should do well a the post-pandemic recovery gathers pace.
The market is waking up to the appeal of Europe’s sustainability-focused industrial market leaders against a backdrop of global fiscal stimulus. Companies with strong balance sheets and a record of generating persistently high cash returns and high levels of recurring revenues were in a robust position already. Add in large amounts of fiscal stimulus focused on building back better through green and digital technology, and the exciting opportunities multiply.
Hands-free access to the office
A stock that will benefit from the return to the office is Assa Abloy (Stockholm: ASSA-B), the global market leader in digital-locking systems and access controls. Assa has persistently generated high cash-flow returns on investment of around 20%. Recurring revenues are very high, with nearly 70% of sales from the aftermarket compared with 30% from new construction. For Assa, the return to the office or hotel doesn’t have to mean five days a week, but just enough to get digital key cards reissued and other access solutions restarted.
What’s more, the post-pandemic new-build market is likely to have a strong emphasis on hands-free access, which plays to Assa’s strengths, and should see a compound annual growth rate of at least 10% maintained over the cycle. At some three times the size of its nearest competitor, Allegion, Assa’s advantage is its size; there is also scope for bolt-on acquisitions in a fragmented market.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Thales (Paris: HO), which makes electrical systems for the aerospace and defence industries, has multiple world-class businesses characterised by ample scope for growth and identifiable barriers to entry (characteristics that allow it to fend off rivals), including a large installed base leading to high levels of recurring revenues. This means the company has the potential to continue to generate persistently high cash returns (off a near-3% dividend yield) set against a favourable valuation of low-teens estimated earnings for 2022.
Global market-leading positions in avionics and air-traffic management systems mean the company is well-placed to benefit from a recovery in aerospace activity post-pandemic. European defence expenditure looks likely to continue to rise from low levels in the face of increasingly complex geopolitics. There are clear signs of recovery in satellites, where Thales forms half of a duopoly position in Europe. The group’s cyber and biometric-identity technology is high-quality, and unique at the price when compared with pure-play peers globally.
Building back better
Kaufman & Broad (Paris: KOF), based in Paris, is one of France’s largest housebuilders. It has a strong record of generating persistently high cash returns, averaging around 20% per annum for the last eight years. Its cash-conversion ratio (how fast capital investment is converted into cash) is excellent, supported by the sale-before completion model, and the balance sheet is robust, characterised by negative net-debt-to-equity of -15% at the end of 2020.
We think Kaufman & Broad is well positioned to build back more sustainably and create jobs. The company’s focus on residential and commercial-to-residential rebuilding, along with its strong environmental and social governance (ESG) credentials, put it in pole position.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Barclays begins paying up to £100 compensation to customers after banking outage
Barclays will pay up to £7.5 million in compensation to customers after its banking services were disrupted by an IT outage
By Daniel Hilton Published
-
Review: Shangri-La Paris – an ode to the world’s best food
Natasha Langan enjoys fine French and Chinese cuisine at the Shangri-La Paris
By Natasha Langan Published
-
The star small and mid-cap stocks income investors have overlooked
Opinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
By Thomas Moore Published
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge Published
-
Chemring Group: an explosive investment opportunity in defence
European states are raising their military spending, and Chemring Group looks well placed to profit
By Rupert Hargreaves Published
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge Published
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field Published
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs Published
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward Published
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves Published